Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Novel bispecific T cell engaging antibodies for treatment of Lyme disease

Award Number: R43AI114214
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/21/2014
PERIOD OF PERFORMANCE END DATE: 07/31/2015

Group Awards By:

View Award Description

Novel bispecific T cell engaging antibodies for treatment of Lyme disease - DESCRIPTION (provided by applicant): Lyme disease (LD) is the most commonly reported tick-borne illness in the United States. According to the recent Center for Disease Control and Prevention report, approximately 300,000 Lyme cases are diagnosed each year. If left untreated, the infection spreads to joints, the heart and the nervous system. In most cases, infections and associated symptoms are eliminated by antibiotic use. Following the antibiotic treatment, however, many patients have persistent or recurrent symptoms characterized by lingering fatigue, pain, or joint and muscle aches. Studies in animal models indicate that Lyme spirochetes may persist following antibiotic therapy. For those patients who do not respond antibiotics, a novel therapy based on bispecific antibodies is proposed. Bispecific T-cell engaging antibodies (BiTe) will used to redirect T cells to borrelial target cells to trigger cytotxic action by T-lymphocytes. In Phase I, single domain nanobodies to human T cell protein CD3 and Lyme bacteria therapeutic target VlsE, DbpA and CRASP-1 with high affinity and specificity will be developed. Isolated nanobodies will be humanized to reduce potential immunogenicity in humans and respective BiTe antibodies will be produced. The activity of BiTe antibodies to the targets will be characterized in in vitro immunoassays and cytotoxicity assays. In Phase II, the BiTe antibody characterization will be extended to animal models infected with Lyme bacteria to demonstrate its anti-Lyme therapeutic effects.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2014 ( Subtotal = $224,849 )
2014	2014	ABZYME THERAPEUTICS LLC	271 GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Allergy and Infectious Diseases Research	000	1	8/15/2014	NEW	$224,849
														Subtotal = $224,849

Grand Total All Awards = $224,849

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel bispecific T cell engaging antibodies for treatment of Lyme disease

Award Number: R43AI114214

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/21/2014

PERIOD OF PERFORMANCE END DATE: 07/31/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer